A Delaware federal jury has determined that a Swiss pharmaceutical company must pay at least $25 million to a smaller competitor over a patent dispute concerning an experimental enema used in the treatment of a severe form of diarrhea. The lawsuit, which captured significant attention within the industry, highlights the continuing high-stakes nature of patent litigation in the biopharmaceutical sector. Detailed insights into the case and its implications can be explored further here.